How do you plan to integrate sotatercept into the current treatment algorithm for PAH, particularly in patients who are stable on existing therapies?  

Sotatercept gained FDA approval to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events e.g., hospitalization for worsening PAH. The pivotal clinical trials enrolled a subset of Group 1 PAH patients who were stable for an extended period on PAH t...